Cost-effectiveness analysis of entecavir versus lamivudine in patients with chronic hepatitis B;Evaluación de la costo-efectividad de entecavir versus lamivudina en pacientes con hepatitis B crónica

Acta Gastroenterologica Latinoamericana

Volumn 38 M4D, Issue 4, 2008, Pages 260-273

  Calcagno, Juan Ignacio ^a   Augustovski, Federico ^a,b,d   Gadano, Adrián ^b   Souto, Alberto ^a   Yuan, Yong ^c  

^a INSTITUTE FOR CLINICAL EFFECTIVENESS AND HEALTH POLICY   (Argentina)

^b HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^c BRISTOL MYERS SQUIBB   (United States)

^d NONE   (Argentina)

Author keywords

Chronic hepatitis B; Entecavir; Hepatic carcinoma; Lamivudine

Indexed keywords

ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; GUANINE; ADEFOVIR;

ANTIVIRAL THERAPY; ARGENTINA; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG COST; DRUG EFFICACY; EXPERIMENTAL MODEL; HEPATITIS B; HUMAN; INFECTION COMPLICATION; INFECTION RISK; LIFESPAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; OUTCOME ASSESSMENT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; VIRUS LOAD; VITAL STATISTICS; ADULT; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; MALE; DECOMPENSATED LIVER CIRRHOSIS; HEALTH CARE SYSTEM; LIVER CARCINOMA; METHODOLOGY; OBSERVATIONAL STUDY;

ADULT; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DECISION MAKING; FEMALE; GUANINE; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE;

EID: 58149152840     PISSN: 03009033     EISSN: 03009033     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Maynard JE. Hepatitis B: global importance and need for control. Vaccine 1990;8(Suppl):S18-S20.
2. Gish RG, Gadano AC. Chronic hepatitis B: current epidemiology in the Americas and implications for management. Journal of Viral Hepatitis 2006;13:787-798. (Pubitemid 44748283)
3. Tanaka J. Hepatitis B epidemiology in Latin America. Vaccine 2000;18(Suppl 1):S17-S19. (Pubitemid 30100457)
4. Fay OH. Hepatitis B in Latin America: epidemiological patterns and eradication strategy. The Latin American Regional Study Group. Vaccine 1990;8(Suppl 2):S100-S106. (Pubitemid 20154772)
5. Torres JR. Hepatitis B and hepatitis delta virus infection in South America. Gut 1996;38(Suppl 2):S48-S55. (Pubitemid 26167506)
6. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003;362:2089-2094. (Pubitemid 38032767)
7. Realdi G, Fattovich G, Hadziyannis S, Schalm SW, Almasio P, Sanchez-Tapias J, Christensen E, Giustina G, Noventa F. Survival and prognostic factors in 366 patients with compensated cirrhosis type B. A multicenter study. J Hepatol 1994;21:656-666. (Pubitemid 24324044)
8. Cabezas C, Gotuzzo E, Escamilla J, Phillips I. Prevalence of serological markers of viral hepatitis A, B and delta in apparently healthy schoolchildren of Huanta, Peru. Rev Gastroenterol Peru 1994;14:123-134.
9. Parana R, Almeida D. HBV epidemiology in Latin America. Journal of Clinical Virology 2005;34(Suppl 1):S130-S133. (Pubitemid 43197760)
10. Dehesa-Violante M, Nunez-Nateras R. Epidemiology of hepatitis virus B and C. Arch Med Res 2007;38:606-611. (Pubitemid 47008933)
11. Liaw YF, Chu CM, Lin DY, Sheen IS, Yang CY, Huang MJ. Age-specific prevalence and significance of hepatitis B e antigen and antibody in chronic hepatitis B virus infection in Taiwan: a comparison among asymptomatic carriers, chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. J Med Virol 1984;13:385-391. (Pubitemid 14102325)
12. Iloeje U, Yang HI, Su J, Jen CL, You SL, Chen CJ. Priditcting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterol 2006;130:989-991. (Pubitemid 43374518)
13. Chen CJ, Yang HL, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH. REVEAL-HVB Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73. (Pubitemid 43042691)
14. Chen CJ. Serum hepatitis B Virus DNA as a predictor of the developement of cirrhosis and hepatocellular carcinoma. Current hepatitis reports 2007;6:7.
15. Li SC, Ong SC, Lim SG, Yeoh KG, Kwong KS, Lee V, Lau J, Wong I, Kung N, Leung WT, Chan HL, Chan FK, Sung JJ, Lee KK. A cost comparison of management of chronic hepatitis B and its associated complications in Hong Kong and Singapore. J Clin Gastroenterol 2005;39:176.
16. Yang BM, Kim CH, Kim JY. Cost of chronic hepatitis B infection in South Korea. J Clin Gastroenterol 2004;38 (Suppl 3):S153-S157.
17. Zhiqiang G, Zhaohui D, Oinhuan W, Dexian C, Yunyun F, Hongtao L, Iloeje UH. Cost of chronic hepatitis B infection in China. J Clin Gastroenterol 2004;38(Suppl 3):S175-S178.
18. Brown RE, De Cock E, Colin X, Antoñanzas F, Iloeje UH. Hepatitis B management costs in France, Italy, Spain, and the United Kingdom. J Clin Gastroenterol 2004;38(Suppl):S169-S174.
19. Lee TA, Veenstra DL, Iloeje UH, Sullivan SD. Cost of chronic hepatitis B infection in the United States. J Clin Gastroenterol 2004;38(Suppl 3):S144-S147.
20. Gagnon YM, Levy AR, Iloeje UH, Briggs AH. Treatment costs in Canada of health conditions resulting from chronic hepatitis B infection. J Clin Gastroenterol 2004;38(Suppl 3):S179-S186.
21. Li SC, Ong SC, Lim SG, Yeoh KG, Kwong KS, Lee V, Lau J, Wong I, Kung N, Leung WT, Chan HL, Chan FK, Sung JJ, Lee KK. A cost comparison of management of chronic hepatitis B and its associated complications in Hong Kong and Singapore. J Clin Gastroenterol 2004;38(Suppl 3):S136-S143.
22. Butler JR, Pianko S, Korda RJ, Nguyen S, Gow PJ, Roberts SK, Strasser SI, Sievert W. The direct cost of managing patients with chronic hepatitis B infection in Australia. J Clin Gastroenterol 2004;38(Suppl):S187-S192.
23. Papatheodoridis GV, Dimou E, Papadimitropoulos V. Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance. Am J Gastroenterol 2002;97:1618-1628. (Pubitemid 34761380)
24. Keeffe EB, Dieterich DT, Han SH, Jacobson IM, Martin P, Schiff ER, Tobias H, Wright TL. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006;4:936-962. (Pubitemid 44118844)
25. Osborn MK, Lok AS. Antiviral options for the treatment of chronic hepatitis B. J Antimicrob Chemother 2006;57:1030-1034. (Pubitemid 44644402)
26. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:1347. (Pubitemid 46374607)
27. Daruich J, Gadano A, Fainboim H, Pessoa M, Cheinquer H. Guía latinoamericana de tratamiento de la hepatitis B crónica. Acta Gastroenterol Latinoam 2007; 37:168-177.
28. Lai C.L, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L. BEHOLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-1020.
29. Chang TT, Gish RG, Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D. BEHOLD AI4633022 Study. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-1010. (Pubitemid 43357804)
30. Iglesias CP, Drummond MF, Rovira J. Health-care decision-making processes in Latin America: problems and prospects for the use of economic evaluation. NEVALAT Project Group. Int J Technol Assess Health Care 2005;21:1-14. (Pubitemid 40229363)
31. Rubinstein A, Belizán M, Discacciati V. Are economic evaluations and health technology assessments increasingly demanded in times of rationing health services? The case of the Argentine financial crisis. Int J Technol Assess Health Care 2007;23:162-168. (Pubitemid 46642724)
32. Drummond MF, Schulpher G. Methods for the Economic Evaluation of Health Care Programmes. Oxford University 2005.
33. Yuan Y, Iloeje U, Hay J, Yao GB. Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese Social Security program. Value Health 2008;11(Suppl 1):S11-S22.
34. Instituto Nacional De Censo y Estadística (INDEC). Consejo Nacional del Empleo, la Productividad y el Salario Mínimo, Vital y Móvil. Resolución 02/2007. Ciudad de Buenos Aires 2007.
35. Instituto Nacional De Estadísticas y Censos (INDEC). Costos de tratamiento. Ciudad de Buenos Aires 2007.
36. Kairos. Búsquedas y consultas de precios. Available from: http://www.kairosweb.com/# 2007.
37. Augustovski F, Ferrante D, Souto A, Ramonet M, Gadano A. Cost-effectiveness analysis of a fully liquid pentavalent vaccine in Argentina (Abstract). International Society for Pharmacoecomics and Outcome Research 2007.
38. Banco de la Nación Argentina. Evolución de la cotización del dólar. [cited 2007 28/12/2007]; Available from: http://www.elnotarioargentino.com.ar/evol-bna-anteriores. htm 2007.
39. Gobierno de la Ciudad de Bueno Aires. Compras y contrataciones. Compras mensuales del Sistema de Salud. [cited 2007 03/01/08]; Available from: http://www.buenosaires. gov.ar/areas/hacienda/compras/comprassalud/ 2007.
40. Instituto Nacional Central Único Coordinador de Ablación e Implante (INCUCAI). Sistema Nacional de Información de Procuración y Trasplante de la República Argentina 2007.
41. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699. (Pubitemid 26079803)
42. Pichon Riviere AR, Souto A, Augustovski F. Base de datos de costos sanitarios Argentinos / Health Care Costs Database - Argentina. Instituto de Efectividad Clínica y Sanitaria. Buenos Aires, Argentina 2007.
43. World Health Organization. Life Tables for WHO Member States 2005.
44. Berck R, Pauker S, Gottlieb J, Klein K, Kassirer J. A convenient approxiamation of life expectancy (the "DEALE"). The American Journal of Medicine 1982;73:9.
45. Bolondi L, Sofia S, Siringo S, Gaiani S, Casali A, Zironi G, Piscaglia F, Gramantieri L, Zanetti M, Sherman M. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001;48:251-259. (Pubitemid 32141852)
46. Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E. European Concerted Action on Viral Hepatitis (EUROHEP). Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 2002;97:2886-2895.
47. Chen CJ, Yang HI, Su J, Jen CL, You SL, Huang GT, Iloeje UH. Reveal HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. Jama 2006;295:65-73. (Pubitemid 43042691)
48. Levy AR, Kowdley K, Iloeje U, Tafesse E, Mukherjee J, Gish R, Bzowej N, Briggs AH. The impact of chronic hepatitis B disease progression on quality of life: a multinational study of health state preferences from infected and uninfected persons. Value Health 2008;11:527-538. (Pubitemid 351712982)
49. Sachs JD. Macroeconomics and Health: Investing in Health for Economic Development. World Health Organisation 2001.
50. World Bank. World Development Indicators database. Total GDP 2006.